TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12612509

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 17
Study: 10681867

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion at acupoints such as Tianshu (St 25), Guanyuan (Ren 4)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Western drugs
Number of subjects: 62
Study: 8760535

Group type: EXPERIMENTAL
Intervention: Primary repair
Number of subjects: 109

Group type: COMPARATOR
Intervention: Diversion (39 colostomies, 14 ileostomies)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Diversion
Number of subjects: 109
Study: 1752926

Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG) induced ovulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spontaneous urinary luteinizing hormone (LH) surge
Number of subjects: 48
Study: 6752877

Group type: EXPERIMENTAL
Intervention: Pirprofen 200 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Pirprofen 400 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Pentazocin 100 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 31449874

Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate hypocaloric diet (Diet HP)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard severe hypocaloric diet (Diet S)
Number of subjects: 270
Study: 29183226

Group type: EXPERIMENTAL
Intervention: Telephone survey of parents regarding attendance for diagnostic tests
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: Reasons for not attending diagnostic tests
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: Overall attendance at the diagnostic level
Number of subjects: 3239
Study: 26572756

Group type: EXPERIMENTAL
Intervention: Football training (FTG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard care control (CON)
Number of subjects: 57
Study: 24903067

Group type: EXPERIMENTAL
Intervention: Lateral wedged insoles (LWIs) - typical wedges
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lateral wedged insoles (LWIs) - supported wedges
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 70
Study: 23034077

Group type: EXPERIMENTAL
Intervention: Use of feedback scales in the Partners for Change Outcome Management System (PCOMS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 75
Study: 18722743

Group type: EXPERIMENTAL
Intervention: SPOTI method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional ACLS course
Number of subjects: 30
Study: 17435410

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 15144369

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including increasing self-efficacy to prevent falls, improving knowledge of medication safety, and decreasing environmental risks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison group (control).
Number of subjects: 120
Study: 11553032

Group type: EXPERIMENTAL
Intervention: PD 123319 (8 microg/min)
Number of subjects: 0
Study: 9623436

Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Macintosh laryngoscope with size 5 blade
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blind intubation with introducer
Number of subjects: 15
Study: 7875184

Group type: EXPERIMENTAL
Intervention: Mizolastine 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mizolastine 45 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triprolidine 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2894357

Group type: EXPERIMENTAL
Intervention: Nitrendipine alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nitrendipine alone or in combination with hydrochlorothiazide or propranolol or both
Number of subjects: 114
Study: 29241976

Group type: EXPERIMENTAL
Intervention: Gender-congruent apologies (female physicians providing affective apologies, male physicians providing cognitive apologies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gender-incongruent apologies (female physicians providing cognitive apologies, male physicians providing affective apologies)
Number of subjects: 0
Study: 27356698

Group type: EXPERIMENTAL
Intervention: Experimented with smoking
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Need for a cigarette first thing in the morning
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Smoking initiation related to age
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Smoking initiation related to gender and living situation
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Smoking initiation related to substance use
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Current smokers related to alcohol consumption
Number of subjects: 326
Study: 24796987

Group type: EXPERIMENTAL
Intervention: CLA (Clarinol A‐80; n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: PLA (sunflower oil; n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 33

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 33
Study: 22628663

Group type: EXPERIMENTAL
Intervention: Intermediate vaginal flora (IVF)
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 1367
Study: 19896172

Group type: EXPERIMENTAL
Intervention: Standard urotherapy combined with biofeedback therapy (Group 1)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard urotherapy only (Group 2)
Number of subjects: 94
Study: 18612862

Group type: EXPERIMENTAL
Intervention: Internet-based clinician-assisted computerized cognitive behavioural therapy programme
Number of subjects: 105

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 105
Study: 16102630

Group type: EXPERIMENTAL
Intervention: SCD Express
Number of subjects: 30

Group type: COMPARATOR
Intervention: SCD Response
Number of subjects: 30
Study: 11919228

Group type: EXPERIMENTAL
Intervention: Complete mesorectum
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Incomplete mesorectum
Number of subjects: 180
Study: 10376129

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8726300

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Naproxen (after 7 days)
Number of subjects: 34
Study: 1686080

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (2 Hz)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz)
Number of subjects: 37
Study: 7131540

Group type: EXPERIMENTAL
Intervention: High-status experimenter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Equal-status experimenter
Number of subjects: 40
Study: 31606445

Group type: EXPERIMENTAL
Intervention: Treosulfan plus fludarabine
Number of subjects: 476

Group type: COMPARATOR
Intervention: Busulfan plus fludarabine
Number of subjects: 476
Study: 31493209

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 28809990

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% spray
Number of subjects: 297

Group type: COMPARATOR
Intervention: Clobetasol 0.05% spray
Number of subjects: 297

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 297

Group type: COMPARATOR
Intervention: 0.1% sodium lauryl sulfate
Number of subjects: 297

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 297

Group type: COMPARATOR
Intervention: Active comparator control (clobetasol spray)
Number of subjects: 297
Study: 25643851

Group type: EXPERIMENTAL
Intervention: Personalized mailed feedback outlining specific risks associated with alcohol use, an educational booklet on alcohol and aging, and the National Institutes of Health Rethinking Drinking: Alcohol and Your Health booklet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 86
Study: 24535654

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 80
Study: 22305243

Group type: EXPERIMENTAL
Intervention: Tactile Massage (TM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Relaxation Exercises
Number of subjects: 53
Study: 19099314

Group type: EXPERIMENTAL
Intervention: Gabapentin preoperatively
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo preoperatively
Number of subjects: 58
Study: 17993363

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (psychoeducational group, treatment adherence support, pharmacotherapy if needed)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study: 15316713

Group type: EXPERIMENTAL
Intervention: 0.65 g alcohol/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12490789

Group type: EXPERIMENTAL
Intervention: Reduced-dose CsA plus concentration-controlled SRL (troughs 10-20 ng/mL; group B, n=100)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Full-dose CsA (microemulsion) plus fixed-dose SRL (2 mg/day; group A, n=97)
Number of subjects: 246
Study: 9661093

Group type: EXPERIMENTAL
Intervention: Right unilateral electroconvulsive therapy (ECT)
Number of subjects: 1
Study: 14689023

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline sulphate (dry powder, Turbuhaler - 0.5 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline sulphate (nebulizer 1% solution in saline - compressed air 6 l/min)
Number of subjects: 47
Study: 3745846

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg q.i.d.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: domperidone 20 mg q.i.d.
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 31971424

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 183
Study: 31718386

Group type: EXPERIMENTAL
Intervention: Gamified attention training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 98

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 98
Study: 30326940

Group type: EXPERIMENTAL
Intervention: Homotopic noxious stimulation group (group A)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Homotopic innocuous stimulation group (group B)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heterotopic noxious stimulation group (group C)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heterotopic innocuous stimulation group (group D)
Number of subjects: 144

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 144
Study: 26945570

Group type: EXPERIMENTAL
Intervention: 1-year group-based behavioral intervention designed to achieve and maintain weight loss
Number of subjects: 692

Group type: COMPARATOR
Intervention: Less intensive control intervention
Number of subjects: 692
Study: 22696251

Group type: EXPERIMENTAL
Intervention: Prior cyclophosphamide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Prior docetaxel
Number of subjects: 49
Study: 22502848

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 20434400

Group type: EXPERIMENTAL
Intervention: EIA plus regional hyperthermia
Number of subjects: 341

Group type: COMPARATOR
Intervention: EIA alone
Number of subjects: 341
Study: 18324951

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (OW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly (OW)
Number of subjects: 0
Study: 18207124

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin + topical prednisolone phosphate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical moxifloxacin + placebo
Number of subjects: 42
Study: 15381937

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus Epirubicin 75 mg/m² (ET)
Number of subjects: 142

Group type: COMPARATOR
Intervention: 5-Fluorouracil 500 mg/m² plus Epirubicin 75 mg/m² and Cyclophosphamide 500 mg/m² (FEC)
Number of subjects: 142
Study: 11416804

Group type: EXPERIMENTAL
Intervention: Kinestherapy and inhaled bronchodilator drugs (salbutamol and/or ipratropium bromide) with a boreal nebulizer, bronchial hygiene, breathing exercises on a Bodyguard Ergometer 990, treated three times per week for twelve weeks.
Number of subjects: 38
Study: 9304426

Group type: EXPERIMENTAL
Intervention: Family physician involvement with a fail-safe system for follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family physician involvement without a fail-safe system for follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall compliance in the study group
Number of subjects: 0
Study: 8439686

Group type: EXPERIMENTAL
Intervention: Aminosyn
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FreAmine HBC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TrophAmine
Number of subjects: 10
Study: 3790399

Group type: EXPERIMENTAL
Intervention: Ethanol consumption (66 g per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (abstained from ethanol for 4 days)
Number of subjects: 8
Study: 31065365

Group type: EXPERIMENTAL
Intervention: CWE (chromoendoscopy with water exchange)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: WE (water exchange)
Number of subjects: 480

Group type: COMPARATOR
Intervention: AI (air insufflation)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: CWE
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: WE
Number of subjects: 480

Group type: COMPARATOR
Intervention: AI
Number of subjects: 480
Study: 30157826

Group type: EXPERIMENTAL
Intervention: Executive Function (EF) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study: 26653612

Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (FIRST group)
Number of subjects: 7170

Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (ADD group)
Number of subjects: 7170

Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily (SWITCH group)
Number of subjects: 7170

Group type: EXPERIMENTAL
Intervention: Gliclazide MR 60 mg once daily
Number of subjects: 7170
Study: 25439972

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT), 8 sessions of 2 hours each
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 22395580

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117
Study: 19156087

Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa/carbidopa/entacapone)
Number of subjects: 34
Study: 17227219

Group type: EXPERIMENTAL
Intervention: hPTH(1-34) 50 microg daily subcutaneously for 1 month
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (13 postmenopausal women with osteoporosis)
Number of subjects: 27
Study: 15471657

Group type: EXPERIMENTAL
Intervention: Functional Interference Estimate (FIE)
Number of subjects: 1337
Study: 11396815

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (1.5 mg retinyl palmitate and 30 mg beta-carotene daily during pregnancy plus 60 mg retinyl palmitate at delivery)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 9594475

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish application
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo varnish application
Number of subjects: 316
Study: 8053282

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg OD
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg OD
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg with diuretics
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 91
Study: 2898244

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) (2 mg/day)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GST) (50 mg/week)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 186
Study: 31599809

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) + total mesorectal excision (TME) in high-risk patients (HiR)
Number of subjects: 401

Group type: COMPARATOR
Intervention: TME alone in high-risk patients (HiS)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: SCRT + TME in low-risk patients (LoR)
Number of subjects: 401

Group type: COMPARATOR
Intervention: TME alone in low-risk patients (LoS)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Low-risk patients (LoR)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: High-risk patients (HiR)
Number of subjects: 401
Study: 29659969

Group type: EXPERIMENTAL
Intervention: 350 mg aspartame/d
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1050 mg aspartame/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0 mg aspartame/d (control group)
Number of subjects: 100
Study: 27271754

Group type: EXPERIMENTAL
Intervention: Posterior cruciate substitution (PS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Posterior cruciate retention (CR)
Number of subjects: 61
Study: 26148063

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis before skin incision
Number of subjects: 410

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis after umbilical cord clamping
Number of subjects: 410
Study: 23704120

Group type: EXPERIMENTAL
Intervention: Cell phone intervention (CPI)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 474
Study: 21154195

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (83 μg or 3,332 IU daily for 1 year)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18506636

Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 21
Study: 16818837

Group type: EXPERIMENTAL
Intervention: Point-of-care rapid influenza test
Number of subjects: 468

Group type: COMPARATOR
Intervention: No rapid influenza test
Number of subjects: 468
Study: 21904686

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg and 8 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10516884

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pramipexole 4.5 mg/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7863370

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0
Study: 2328559

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 15
Study: 7011249

Group type: EXPERIMENTAL
Intervention: High-dose haloperidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-dose haloperidol
Number of subjects: 20
Study: 30448517

Group type: EXPERIMENTAL
Intervention: CytoSorb
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 28705208

Group type: EXPERIMENTAL
Intervention: Quarterly audit and feedback interventions with different comparators and framing
Number of subjects: 56000

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 56000
Study: 27140801

Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (0.06 mg/kg)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (0.02 mg/kg)
Number of subjects: 368
Study: 23471208

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (casein, 30 g/d)
Number of subjects: 69
Study: 21419356

Group type: EXPERIMENTAL
Intervention: Greek traditional dance courses and upper body training (1 hour, 3 sessions/week) for 24 weeks
Number of subjects: 27
Study: 19725255

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 60
Study: 17692748

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 22
Study: 15462544

Group type: EXPERIMENTAL
Intervention: Posttraumatic Growth Inventory (PTGI) linked to a specific stressful event
Number of subjects: 276

Group type: COMPARATOR
Intervention: Posttraumatic Growth Inventory (PTGI) not linked to specific events
Number of subjects: 276
Study: 11232690

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1273
Study: 9402351

Group type: EXPERIMENTAL
Intervention: Furazolidone combined with bismuth subsalicylate and amoxicillin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Follow-up endoscopy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Testing for antibodies to H. pylori
Number of subjects: 105